logo

For the Inventor, By the Inventor

San Diego, CA, United States of America

Acadia Pharmaceuticals Inc.


USPTO Granted Patents = 94

% Expired Patents = 41.5



Trademarks = 14

Forward Citations = 1,356

Loading Chart...
Loading Chart...

88 inventors (with patents filed for the assignee):

goldMedal Mark R Brann (25 out of 25 patents)

silverMedal Carl-Magnus A Andersson (25 out of 26 patents)

bronzeMedal Roger Olsson (19 out of 20 patents)

4.  David M Weiner (19 out of 20 patents)

5.  Allan K Uldam (19 out of 19 patents)

6.  Robert E Davis (17 out of 145 patents)

7.  Bo-Ragnar Tolf (16 out of 16 patents)

8.  Nathalie Schlienger (15 out of 15 patents)

9.  Kristian Norup Koch (11 out of 11 patents)

10.  Niels Skjaerbaek (9 out of 9 patents)

11.  Mikkel Boas Thygesen (7 out of 7 patents)

12.  Ethan S Burstein (6 out of 6 patents)

13.  Marlon Carlos (6 out of 23 patents)

14.  Magnus Gustafsson (6 out of 7 patents)

15.  Eva Louise Hansen (6 out of 7 patents)


Core Competencies:
Pimavanserin
Neuro-attenuating Ketamine
Selective Serotonin Agonists
Muscarinic Agonists
Trofinetide
Estrogen Receptors
Thiazoline Compounds
Pain Treatment
Azacyclic Compounds
5-HT2A Receptor
Monoamine Receptor Modulators
Carbamide Derivatives

94 patents:

1. RE50805 - Single-layer oral dose of neuro-attenuating ketamine (2026-02-24),
2. 12492167 - Crystalline forms of trofinetide (2025-12-09),
3. 12466783 - Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods (2025-11-11),
4. 12139477 - Compounds, salts thereof and methods for treatment of diseases (2024-11-12),
5. 11844764 - Agitation process for preparing a carbetocin drug product (2023-12-19),
6. 11840515 - Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c (2023-12-12),
7. 11827600 - Crystalline forms of trofinetide (2023-11-28),
8. 11464768 - Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis (2022-10-11),
9. 11452721 - Formulations of pimavanserin (2022-09-27),
10. 11440884 - Compounds, salts thereof and methods for treatment of diseases (2022-09-13),
11. 11345693 - Compounds, salts thereof and methods for treatment of diseases (2022-05-31),
12. 11191757 - Combination of pimavanserin and cytochrome P450 modulators (2021-12-07),
13. 11161826 - Manufacturing methods and polymorphs of a thiazoline anti-hyperalgesic agent (2021-11-02),
14. 11135211 - Pimavanserin for treating impulse control disorder (2021-10-05),
15. 11091473 - Compounds for pain treatment, compositions comprising same, and methods of using same (2021-08-17),
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. With a strong emphasis on neuroscience, ACADIA is committed to improving the lives of patients suffering from neurological and related psychiatric disorders.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Acadia Pharmaceuticals Inc.
94 Patents

#66 in San Diego, CA

#927 in California

#3,976 in US

#8,178 in the World

San Diego, CA (US)
San Diego, CA, United States of America

Acadia Pharmaceuticals Inc.

Forward Citations = 1,356

88 inventors:

goldMedal Mark R Brann (25 out of 25 patents)

silverMedal Carl-Magnus A Andersson (25 out of 26 patents)

bronzeMedal Roger Olsson (19 out of 20 patents)

4.  David M Weiner (19 out of 20 patents)

5.  Allan K Uldam (19 out of 19 patents)

Please report any incorrect information to [email protected]
Loading…